effect overlay
activetrials
Placeholder
Stentrode
FOCUS-AUS Stentrode 3

Functional Outcomes and Control Using Synchron BCI Australia (FOCUS-AUS) - Stentrode 3

HREC: 2026.021
Principal Investigator: Prof Peter Mitchell
Coordinator contact:
Funding: Commercial
Placeholder
Brain Tumour/Neurosurgery
Coherence CIPHER

A First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma

HREC: 2026.016
Principal Investigator: A/Prof Andrew Morokoff
Coordinator contact:
Funding: Commercial
Stroke
Stroke
TENACITY

A Phase III, prospective, randomized, open-label, blinded endpoint assessment (PROBE) to assess efficacy and safety of IV tenecteplase vs standard of care in patients with acute ischemic stroke (including wake-up stroke), last known well >4.5 h with imaging evidence of salvageable ischemic tissue

HREC: 2025.290
Principal Investigator: Prof Bruce Campbell
Coordinator contact:
Funding: Commercial
Stroke
Stroke
SELECT LATE

Medical Management with Endovascular Thrombectomy versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well

HREC: 2025.219
Principal Investigator: Prof Bruce Campbell
Coordinator contact:
Funding: Non-Commercial
Multiple sclerosis
Multiple Sclerosis
STOP-MS

Phase III, multicentre, randomised, double-blinded, placebocontrolled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression

HREC: 2024.415
Principal Investigator: Dr Ai-Lan Nguyen
Coordinator contact:
Funding: Non-Commercial